Michaël Sébag

Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma

Jonathan J. Keats, Rafaël Fonseca, Marta Chesi et al. · Cancer Cell · 2007 · 988 citations · Full text

Medicine, Cell Biology, Molecular Biology +11

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Sagar Lonial, Brendan M. Weiss, Saad Z. Usmani et al. · The Lancet · 2016 · 850 citations

Medicine, Oncology, Pharmacotherapy +14

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies

Marta Chesi, Davide F. Robbiani, Michaël Sébag et al. · Cancer Cell · 2008 · 383 citations · Full text

Medicine, Genetics, Oncology +14

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Ravi Vij, Michael Wang, Jonathan L. Kaufman et al. · Blood · 2012 · 254 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13